首页    期刊浏览 2024年11月25日 星期一
登录注册

文章基本信息

  • 标题:Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia
  • 其他标题:Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia
  • 本地全文:下载
  • 作者:Joaqui, Vanessa Bedoya ; Gómez, Nathalia Buitrago ; Ortiz, Reinaldo Carvajal
  • 期刊名称:Archives of Endocrinology and Metabolism
  • 印刷版ISSN:2359-3997
  • 出版年度:2021
  • 卷号:65
  • 期号:1
  • 页码:49-59
  • DOI:10.20945/2359-3997000000319
  • 出版社:Archives of Endocrinology and Metabolism
  • 摘要:Objectives: To evaluate the effectiveness of adding dapagliflozin as an intensification strategy for the treatment of patients with uncontrolled type 2 diabetes mellitus (T2DM). Materials and methods: A historical cohort study was conducted in 123 adult patients over 18 years old who were diagnosed with uncontrolled T2DM, who received dapagliflozin add-on to their dual base treatment: metformin plus glibenclamide (n = 32), metformin plus saxagliptin (n = 29), metformin plus exenatide (n = 28), or metformin plus insulin (n = 34). The endpoints were evaluated using analysis of variance. Results: All the patients completed a 52-week follow-up. Overall, 52.85% of patients were female, the Hispanic population represented the largest proportion of patients in all groups (60.98%), and the mean ± SD patient age and body weight were 55.05 ± 7.58 years and 83.55 ± 9.65 kg, respectively. The mean ± SD duration of T2DM, glycated hemoglobin (HbA1c), and fasting plasma glucose (FPG) were 5.93 ± 2.98 years, 8.1 ± 0.53%, and 166.03 ± 26.80 mg/dL, respectively. The grand mean changes of HbA1c, FPG, body weight and blood pressure showed a decreasing trend during the study period and it was statistically significant in all groups (p-value = <0.001). The proportion of patients achieving HbA1c target (<7%) was highest in the group that used a dapagliflozin add-on to metformin plus saxagliptin. Conclusion: The addition of dapagliflozin as an alternative for intensification of dual therapy consistently improved, not only FPG and HbA1c, but also body weight and blood pressure, with statistically significant results.
  • 关键词:Diabetes mellitus; combined modality therapy; hypoglycemic agents.
  • 其他关键词:Diabetes mellitus;combined modality therapy;hypoglycemic agents
国家哲学社会科学文献中心版权所有